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Estimating the most eﬃ  cient allocation of interventions to 
achieve reductions in Plasmodium falciparum malaria burden 
and transmission in Africa: a modelling study
Patrick G T Walker, Jamie T Griﬃ  n, Neil M Ferguson, Azra C Ghani
Summary
Background Reducing the burden of malaria is a global priority, but ﬁ nancial constraints mean that available resources 
must be allocated rationally to maximise their eﬀ ect. We aimed to develop a model to estimate the most eﬃ  cient 
(ie, minimum cost) ordering of interventions to reduce malaria burden and transmission. We also aimed to estimate 
the eﬃ  ciency of diﬀ erent spatial scales of implementation.
Methods We combined a dynamic model capturing heterogeneity in malaria transmission across Africa with ﬁ nancial 
unit cost data for key malaria interventions. We combined estimates of patterns of malaria endemicity, seasonality in 
rainfall, and mosquito composition to map optimum packages of these interventions across Africa. Using non-linear 
optimisation methods, we examined how these optimum packages vary when control measures are deployed and 
assessed at national, subnational ﬁ rst administrative (provincial), or ﬁ ne-scale (5 km² pixel) spatial scales.
Findings The most eﬃ  cient package in a given setting varies depending on whether disease reduction or elimination 
is the target. Long-lasting insecticide-treated nets are generally the most cost-eﬀ ective ﬁ rst intervention to achieve 
either goal, with seasonal malaria chemoprevention or indoor residual spraying added second depending on 
seasonality and vector species. These interventions are estimated to reduce malaria transmission to less than one case 
per 1000 people per year in 43·4% (95% CI 40·0–49·0) of the population at risk in Africa. Adding three rounds of 
mass drug administration per year is estimated to increase this proportion to 90·9% (95% CI 86·9–94·6). 
Further optimisation can be achieved by targeting policies at the provincial level, achieving an estimated 32·1% 
(95% CI 29·6–34·5) cost saving relative to adopting country-wide policies. Nevertheless, we predict that only 
26 (95% CI 22–29) of 41 countries could reduce transmission to these levels with these approaches.
Interpretation These results highlight the cost–beneﬁ ts of carefully tailoring malaria interventions to the ecological 
landscape of diﬀ erent areas. However, novel interventions are necessary if malaria eradication is to be achieved.
Funding Bill & Melinda Gates Foundation, UK Medical Research Council.
Copyright © Walker et al. Open Access article distributed under the terms of CC BY.
Introduction
The 21st century has seen an unprecedented ﬁ nancial 
commitment towards reducing the burden of 
Plasmodium falciparum malaria.1 Over the past decade, the 
proportion of the population of sub-Saharan Africa (the 
region with most global cases of malaria and deaths from 
the disease) with access to an insecticide-treated net has 
increased from 4% to 67% (95% CI 61–71) between 2004 
and 2015, with an estimated 189 million long-lasting 
insecticide-treated nets delivered in 2014 alone.2 This rapid 
scale-up in vector control has coincided with substantial 
improvements in access to prompt diagnosis and 
treatment using highly eﬀ ective artemisinin combination 
therapies and chemoprevention within core risk groups, 
including young children and pregnant women.3 These 
eﬀ orts have contributed to an estimated 26% reduction in 
the global incidence of clinical malaria and roughly 
4·3 million deaths averted between 2000 and 2013.3
To date, with one exception (the recommendation of 
seasonal malaria chemoprevention),4 universal coverage 
has been promoted—namely, all interventions are 
recom mended in all settings. However, malaria trans-
mission shows considerable variation at all spatial scales, 
ranging from hotspots within villages to diﬀ erences 
between countries and continents.5,6 Previous analyses 
have looked at how the cost-eﬀ ectiveness of diﬀ erent 
combinations of interventions to reduce clinical disease 
and the morbidity associated with malaria vary according 
to diﬀ erent factors aﬀ ecting transmission.7–10 However, to 
date, no one has attempted to assess comprehensively 
how the optimum combinations of interventions to 
achieve malaria control targets vary across Africa as a 
result of such heterogeneity. In view of the current 
plateau in available funding for further malaria control 
and the subsequent shortfall in resources to achieve 
global goals,1,3,11,12 there is a need to develop a rational 
basis to allocate the ﬁ nite resources to achieve the 
greatest and most equitable eﬀ ect.
To address this problem, we combined an existing 
malaria transmission model with estimates of the ﬁ nancial 
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cost of diﬀ erent interventions to capture the non-linear 
dynamics of intervention eﬀ ect and expenditure. We used 
this model to estimate the most cost-eﬃ  cient strategies to 
achieve goals for reducing burden and transmission across 
a wide range of environments representative of areas in 
which the disease is currently prevalent in Africa.
Methods
Modelling speciﬁ cation and sampling framework
Using an individual-based mathematical model of 
P falciparum malaria transmission (panel),13,14 we attempted 
to reﬂ ect the range of transmission settings across Africa, 
while maintaining a sampling framework that was 
comput ationally feasible. We simulated 288 baseline trans-
mission settings comprising 18 trans mission intensity 
strata (1% prevalence, then 5–85% prevalence in incre-
ments of 5%), four seasonality proﬁ les, and four vector 
behaviours, ranging from mainly endophilic (indoor 
resting) and endophagic (indoor feeding) vectors, such as 
Anopheles gambiae sensu stricto or Anopheles funestus, to a 
vector with a lower human-biting index and higher 
propensity to feed and rest outdoors, such as 
Anopheles arabiensis (ﬁ gure 1; appendix pp 2–8). For every 
setting, we simulated the eﬀ ect of intervention packages 
over a 20-year time horizon, with all possible combinations 
of long-lasting insecticide-treated nets, indoor residual 
spraying, and seasonal malaria chemo pre vention, ranging 
from 0% to 90% coverage in 15% increments. This 
simulation generated 98 784 scenarios.
We achieved scale-up of long-lasting insecticide-treated 
nets by providing a quarter of the total required nets for 
Research in context
Evidence before this study
We searched PubMed with no date restriction for publications 
in English that combined models of malaria transmission with 
estimates of the resources needed to implement interventions, 
with the terms (“resource allocation” OR “optimal intervention” 
OR “cost minimisation” OR “cost eﬀ ectiveness” OR 
“cost-eﬀ ectiveness” OR “economic evaluation”) AND (“model” 
OR “modelling”) AND (“malaria” OR “falciparum” OR 
“plasmodium”). Our search yielded 147 results, 17 of which 
were judged relevant. Publications included various analyses of 
the cost-eﬀ ectiveness of one or more malaria control 
interventions, sometimes taking into account ecological factors 
such as transmission intensity and vector behaviour and 
assessing how these aﬀ ect the most cost-eﬀ ective combination 
of interventions.
Added value of this study
To our knowledge, our study is the ﬁ rst that has attempted to 
estimate the optimum combination of interventions to achieve 
milestones for malaria burden and transmission reduction and 
to quantify how these packages are likely to vary across Africa. 
It is also the ﬁ rst study, to our knowledge, that looks at the 
extent to which the resources needed to achieve these targets 
can be reduced using control policies tailored to local ecology at 
the subnational ﬁ rst administrative (provincial) level.
Implications of all the available evidence
After universal coverage of long-lasting insecticide-treated 
nets, the optimum subsequent package of interventions diﬀ ers 
depending on whether the target is a rapid reduction in malaria 
burden or sustained reductions in transmission. Nevertheless, 
currently recommended interventions are unlikely to achieve 
elimination in most malaria-endemic countries in Africa. 
New transmission-reducing interventions—eg, mass drug 
administration—could increase the number of countries in 
which elimination is feasible. For all policies, in countries with a 
high degree of heterogeneity in transmission, we ﬁ nd that 
interventions tailored to the provincial level are substantially 
more cost-eﬃ  cient than are national policies. Moreover, these 
provincial-level policies typically capture most of the 
cost savings that could be obtained when attempting to 
achieve pre-elimination levels of transmission with ﬁ ner spatial 
(5 km² pixel) stratiﬁ cation. 
Panel: Summary of the model
We used an individual-based simulation model of the 
transmission dynamics and clinical burden of 
Plasmodium falciparum malaria, incorporating:
• Acquired immunity, which alters the likelihood that 
infection results in clinical disease, modiﬁ es onward 
infectivity to mosquitoes, aﬀ ects the detectability of 
infection, and modiﬁ es the duration of parasitaemia
• Mosquito dynamics and behaviour relevant to control, 
including lifespan, density-dependent larval 
development, and feeding and resting behaviour
• Seasonality in larval carrying capacity informed by 
seasonal patterns in rainfall
• Characteristics of various ﬁ rst-line treatments for malaria, 
with proﬁ les based on pharmacokinetic/
pharmacodynamic (PK/PD) model ﬁ ts to trial data
• A process-based model of the eﬀ ect of vector control 
(long-lasting insecticide-treated nets [LLINs] and indoor 
residual spraying [IRS]), with parameters taken from 
detailed hut studies and ﬁ tted to intervention trial data
• Population-based, drug-based, intervention strategies, 
including seasonal malaria chemoprevention and mass 
drug administration, informed by PK/PD model ﬁ ts to 
the individual drug properties and calibrated against 
trial data
• Realistic intervention variables, including attrition of 
LLINs due to wear and tear, waning of insecticides used 
within IRS or LLINs, and prespeciﬁ ed correlation between 
interventions and rounds of the same intervention 
See Online for appendix
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each of the ﬁ rst 4 years of roll-out and subsequently 
renewing these every 4 years, with killing and 
repellency ﬁ tted to hut trial data as described previously14 
and with a half-life of eﬀ ectiveness of 2·64 years, 
reﬂ ecting a long-lasting insecticide.16 We simulated 
indoor residual spraying with eﬃ  cacy parameters based 
on a pirimiphos-methyl capsule-suspension compound 
(appendix pp 8–14), with killing and repellency 
parameters based on experimental hut trial data17,18 and 
longevity based on cone assay data collated by the WHO 
Pesticide Evaluation Scheme (WHOPES).19 We simulated 
seasonal malaria chemo prevention assuming that 
three monthly doses of sulfadoxine-pyrimethamine and 
amodiaquine were given to children aged 6–59 months;4 
we estimated the duration of prophylaxis from trial data,20 
with the timing of the second dose of sulfadoxine-
pyrimethamine and amodiaquine calibrated to coincide 
with the annual peak in transmission. We simulated 
mass screen and treatment by using a rapid diagnostic 
test (assumed to have similar accuracy to microscopy)21 
and by providing dihydroartemisin-piperaquine (rINN, 
artenimol-piperaquine) to individuals with a positive 
result.8 For mass drug administration, we assumed that 
all individuals received dihydroartemisin-piperaquine 
irrespective of infection status. We assumed 90% 
coverage and implementation of either one, two, or three 
rounds of mass drug administration per year, with 
rounds timed to maximise reduction in prevalence 
5 years after implementation (appendix pp 14, 15).
When we looked at optimum packages to achieve pre-
elimination status, we presumed that achieving robust 
surveillance would be a prerequisite, so we assumed 80% 
of clinical disease episodes received appropriate and 
eﬀ ective artemisinin combination treatment in all 
scenarios. We also did a secondary analysis looking at 
optimum packages to reduce burden under the assumption 
that only 40% of cases received artemisinin combination 
treatment (appendix pp 19–23). For every intervention, 
we maintained coverage by redistributing the intervention 
to the same individuals within the population during 
every round. We assumed no correlation between the 
interventions an individual receives.
Resource calculation
We added the median unit procurement cost of a long-
lasting insecticide-treated net (US$5·00 [IQR 4·50–6·60]), 
obtained from a review in west and central Africa,22 to the 
median cost of delivering a net ($1·58), taken from a 
systematic review of costs.23 We inﬂ ated these 2009 values 
to 2012 prices with a US$ inﬂ ation rate calculator to give 
a median cost per bednet distributed of $7·03 
(IQR 6·51–8·24). For indoor residual spraying, we used 
the median cost per person per year protected of 
campaigns using pirimiphos-methyl, which we obtained 
from the President’s Malaria Initiative Indoor Residual 
Spraying Country Programs,24 giving a cost estimate of 
$8·80 per person per year in 2012. The cost in 2012 of 
three rounds of seasonal malaria chemoprevention per 
child using door-to-door delivery was estimated at $6·10 
in Senegal25 and $4·40 in Mali;26 we used the average of 
these two estimates ($5·25). To reﬂ ect the fairly sparse 
data for costs of seasonal malaria chemoprevention and 
indoor residual spraying, compared with data for long-
lasting insecticide-treated nets, we allowed the prices of 
these two interventions to vary between double and half 
these point estimates, according to a triangular 
distribution (table 1; appendix pp 16, 17). 
For the non-drug costs of mass screen and treatment, 
we used a 2007 cost estimate of $5·08,27 inﬂ ated to 2012 
values. This estimate is based on the assumption that 
A Seasonality B Vector composition C Transmission intensity
 Perennial
 Double peak
 Seasonal
 Very seasonal
 A.g/A.f only
 A.g/A.f dominant
 Mixed
 Arabiensis only 20
Prevalence in 
2–10 year olds (%)
40 60 80
Figure 1: Deﬁ ning transmission settings across Africa
(A) Distribution of the four seasonality templates based on rainfall patterns. (B) Vector species distribution for three key species groupings, based on presence and 
absence data.15 A.g=Anopheles gambiae sensu stricto. A.f=Anopheles funestus. Arabiensis=Anopheles arabiensis. Mixed=all three species. (C) Estimates of malaria 
prevalence (blood ﬁ lm positivity) in children aged 2–10 years in 2000, back-calculated from estimates made for 2010,6 using country-based estimates of scale-up for 
long-lasting insecticide-treated nets.
For the US$ inflation rate 
calculator see http://www.
usinflationcalculator.com/
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the intervention uses community health workers already 
trained to manage fever presumptively and who are able 
to reach eight households per day. For the non-drug 
costs of mass drug administration, we assumed that 
remuneration, supervision, and training were 50% of 
the costs for mass screen and treatment, and we removed 
the unit costs of the rapid diagnostic test, lancet, and 
sterile gloves needed to provide diagnosis. This 
calculation resulted in a per-person non-drug cost of 
$2·98. Since the age proﬁ le of individuals with 
asymptomatic infection for mass screen and treatment, 
and that of the overall population for mass drug 
administration, is likely to be substantially older than 
the age distribution of those who typically have 
symptomatic malaria, we estimated an average cost of 
$1·65 for a curative course of dihydroartemisin-
piperaquine, by taking into account the age structure of 
the population and age-dependent dosing recom-
mendations.8 For treatment of uncomplicated malaria, 
we assumed a cost of $2·50 per course, reﬂ ecting the 
cost of providing artemether-lumefantrine to a child 
after a positive rapid diagnostic test result.8 To 
incorporate uncertainty in the cost of mass drug 
administration, we varied these costs between half and 
double their point estimates with a triangular 
distribution (table 1).
Mapping optimum intervention packages
We deﬁ ned an optimum intervention combination for a 
given target as the combination that achieved this target 
at minimum cost. Across our 288 baseline settings, we 
compared the most eﬃ  cient interventions to achieve 
either a 75% reduction in the burden of clinical disease 
from levels in 2000 (equivalent to the 2015 target within 
the Global Malaria Action Plan)28 within a 5-year 
timeframe or a pre-elimination threshold of less than 
one case per 1000 population per year29 at equilibrium 
(simulated over a 20-year timespan to avoid rebounds in 
incidence associated with this loss of immunity). We also 
did sensitivity analyses to assess the robustness of these 
estimated optimum packages to uncertainty in the model 
parameters determining the natural dynamics of 
infection and the eﬀ ectiveness and costs of the three 
diﬀ erent interventions (appendix pp 19–23).
We divided Africa into 0·2° × 0·2° (approximately 5 km²) 
pixels and matched every pixel to one of the 288 baseline 
settings, based on transmission intensity, seasonality, and 
vector bionomics, according to three metrics available at 
this resolution (ﬁ gure 1). First, we used estimates of 
rainfall between 2002 and 2008,30 smoothed by Fourier 
transform and matched to the four diﬀ erent seasonal 
patterns sampled using least squares estimation. Second, 
we based the presence and absence of the three vectors 
across Africa on estimates published by the Malaria Atlas 
Project.31 Finally, we projected malaria prevalence (blood 
ﬁ lm positivity) in children aged 2–10 years in 2010 using 
data published by the Malaria Atlas project6 and back-
calculated to 2000 values with the model, calibrated to 
country-level estimates of insecticide-treated net scale-up 
and the appropriate vector and seasonality proﬁ le 
(appendix pp 15, 16).
We considered the optimum package to achieve our 
targets within every pixel; however, implementation or 
assessment of policies at such a local level is unlikely to 
be operationally feasible. Therefore, we also investigated 
the outcomes of optimising policies and monitoring 
outcomes at both the country level and the subnational 
ﬁ rst administrative (provincial) level. Throughout, we are 
forced to ignore local connectivity between pixels. 
To estimate the most eﬃ  cient policy, we developed a 
stochastic simulated annealing algorithm (appendix 
pp 17–19).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Across all settings, long-lasting insecticide-treated nets 
were predicted to be the most resource-eﬃ  cient 
intervention to reduce the burden of malaria disease 
(ﬁ gure 2A). Nets alone were suﬃ  cient to reach our 
clinical incidence target in settings with baseline parasite 
prevalence between 40% (ie, for areas with the more 
exophilic and zoophilic vector A arabiensis) and 50% (ie, 
for areas with the more endophilic and anthropophilic 
vectors A funestus and A gambiae sensu stricto). In areas 
of higher transmission, where scale-up of long-lasting 
insecticide-treated nets alone was insuﬃ  cient to reach 
the target, seasonal malaria chemoprevention was 
generally more resource-eﬃ  cient than was indoor 
residual spraying and, hence, was the second intervention 
to be included (ﬁ gure 2A). However, in areas with less 
seasonality in transmission or where vectors were highly 
indoor resting, indoor residual spraying entered the 
Estimate 
(US$, 2012)
Uncertainty 
distribution
Cost of distributing long-lasting insecticide-treated nets22 $7·03 Uniform (6·51–8·24)
Cost of indoor residual spraying (per person per year)24 $8·80 Triangle (4·40–17·60)
Cost of three rounds of seasonal malaria chemoprevention (per child 
per year)25,26
$5·25 Triangle (2·63–10·50)
Non-drug cost of mass screen and treatment (per person per round)27 $5·63 Not done*
Non-drug cost of mass drug administration (per person per round)27 $2·98 Triangle (1·49–5·96)
Full course of dihydroartemisin-piperaquine8 $1·65 Triangle (0·83–3·30)
Treatment of uncomplicated malaria with artemether-lumefantrine8 $2·50 Triangle (1·25–5·00)
*Uncertainty analysis was not done because we estimate that mass drug administration achieves the target in a 
substantially greater number of settings than does mass screen and treatment.
Table 1: Unit costs for interventions 
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most eﬃ  cient package once moderate levels of coverage 
of seasonal malaria chemoprevention were achieved 
(ﬁ gure 2A). Sensitivity analyses of these optimum 
packages showed that ﬁ ndings were robust to para-
meter uncertainty in the natural history of infection, 
inter vention eﬀ ectiveness parameters, costs of the inter-
vention, and the assumed level of treatment coverage 
(appendix pp 19–23). After translation of these ﬁ ndings 
to the epidemiological strata within Africa, in most 
settings, either long-lasting insecticide-treated nets alone 
or nets in combination with seasonal malaria chemo-
prevention were the most resource-eﬃ  cient intervention 
packages to achieve a 75% reduction in disease over a 
5-year time horizon (ﬁ gure 3A).
By contrast, when the goal was to reduce transmission 
to pre-elimination levels (less than one case per 
1000 population per year), indoor residual spraying 
generally replaced seasonal malaria chemoprevention as 
the more eﬀ ective second intervention in an optimum 
package (ﬁ gure 2B), a ﬁ nding that was similarly robust to 
parameter uncertainty (appendix pp 19–23). However, in 
simulations with 90% coverage of all three interventions, 
pre-elimination status could be achieved in just 48·6% 
(95% CI 44·5–52·8) of areas in mainland Africa, 
representing 43·4% (40·0–49·0) of the population at risk 
(ﬁ gure 3B).
Inclusion of intensive mass drug administration (90% 
coverage at every round) within intervention packages 
increased the proportion of the population in whom pre-
elimination was achievable to 74·9% (95% CI 72·3–81·3) 
with one round of treatment per year, 81·6% (81·3–88·4) 
after two rounds per year, and 91·4% (85·2–93·2) with 
three rounds per year (ﬁ gure 3D). For mass screen and 
treatment, the equivalent percen tages were 56·5% 
(54·0–64·8), 63·8% (58·7–70·4), and 81·4% (73·0–89·8; 
ﬁ gure 3C). When included in the overall package of 
interventions needed to achieve the pre-elimination 
target, mass drug administration was usually added as 
the second intervention after long-lasting insecticide-
treated nets in areas with more outdoor-resting 
mosquitos. In areas with highly indoor-resting 
mosquitoes, mass drug administration was generally the 
third most incrementally cost-eﬃ  cient intervention (after 
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Figure 2: Optimum packages of currently available malaria control methods
In every three-dimensional ﬁ gure, the wire frame plots the percentage of the 
at-risk population covered with the three interventions within the optimum 
intervention package, with increasing baseline prevalence. The spheres are 
colour-coded to reﬂ ect the baseline prevalence in every scenario and are sized 
proportionally to the resources needed to implement the package (US$ at 2012 
levels). Missing spheres denote that no sampled package achieved the given 
target within the required timeframe. LLIN=long-lasting insecticide-treated 
nets. IRS=indoor residual spraying. SMC=seasonal malaria chemoprevention. 
(A) Optimum packages to reduce clinical disease by 75% within 5 years after 
implementation, from a 2000 baseline with diﬀ erent seasonality proﬁ les and 
vector proﬁ les. (B) Equivalent ﬁ gure with a target of achieving pre-elimination 
levels of transmission (less than one case per 1000 population per year) within 
20 years after implementation.
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long-lasting insecticide-treated nets and indoor residual 
spraying). However, because these areas usually have 
higher transmission intensity, achieving pre-elimination 
in these settings is predicted to require a combination of 
all three interventions (ﬁ gure 3D).
The spatial scale at which elimination milestones are 
monitored is likely to be important in terms of whether 
areas achieve targets. Pre-elimination levels of 
transmission were predicted to be achievable in 90·9% 
(95% CI 86·9–94·6) of mainland Africa under a package 
of long-lasting insecticide-treated nets, indoor residual 
spraying, and three rounds of mass drug administration 
per year when assessed at the 5 km² pixel level. However, 
when assessed at a national level, only 26 (95% CI 22–29) 
A B
C D
Optimum package
 LLIN
 LLIN + IRS
 LLIN + SMC
 LLIN + IRS + SMC
 Not possible
Optimum package
 LLIN
 LLIN + IRS
 LLIN + SMC
 LLIN + IRS + SMC
 Not possible
Optimum package
 LLIN
 LLIN + IRS
 LLIN + MSAT
 LLIN + IRS + MSAT
 Not possible
Optimum package
 LLIN
 LLIN + IRS
 LLIN + MDA
 LLIN + IRS + MDA
 Not possible
Figure 3: Optimum packages with diﬀ erent drug-based strategies
IRS=indoor residual spraying. LLIN=long-lasting insecticide-treated nets. MDA=mass drug administration. MSAT=mass screen and treatment. SMC=seasonal malaria 
chemoprevention. (A) Optimum package within each 5 km² pixel to reduce clinical incidence by 75% within 5 years from year 2000 levels, with combinations of LLIN, 
IRS, and SMC. (B) Optimum package within each 5 km² pixel to achieve pre-elimination levels of transmission (less than one case per 1000 per person per year) within 
20 years, with combinations of LLIN, IRS, and SMC. (C) Optimum package within each 5 km² pixel to achieve pre-elimination levels of transmission (less than one case 
per 1000 per person per year) within 20 years, with one, two, or three rounds per year of MSAT instead of SMC, at 90% coverage. (D) Optimum package within each 
5 km² pixel to achieve pre-elimination levels of transmission (less than one case per 1000 per person per year) within 20 years, with MDA replacing MSAT. 
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of 41 countries were predicted to achieve pre-elimination 
status, representing just 72·3% (95% CI 45·0–79·4) of 
the total area of Africa and 50·5% (32·9–73·7) of its 
population. Furthermore, some countries can achieve 
the pre-elimination threshold even when pockets of 
higher transmission remain. However, if the target needs 
to be achieved uniformly across the country, then the 
task of achieving pre-elimination is substantially harder, 
with only 22 (95% CI 20–25) countries achieving pre-
elimination in all subnational ﬁ rst administrative units 
(provincial level) in any of our scenarios, and only 
20 (18–22) countries achieving the goal across 5 km² 
pixels.
Within the 26 countries in which we estimated pre-
elimination to be achievable at the national level with a 
package of long-lasting insecticide-treated nets, indoor 
residual spraying, and three rounds of mass drug 
administration per year, we estimated that policies 
optimised at the provincial level would lead to a median 
40·6% (IQR 18·5–52·5) per country reduction in 
resources needed to achieve pre-elimination, relative to a 
country-wide strategy (ﬁ gure 4; table 2). For interventions 
implemented at a 5 km² pixel resolution, the median 
reduction was 59·4% (40·1–66·4). In countries where 
pre-elimination might be possible using these tools, the 
total cost of provincial policies was estimated to be 
32·1% (IQR 29·6–34·5) lower than the cost for countries 
adopting optimum country-level policies (table 2), which 
is 60·1% (56·9–62·5) of the total savings theoretically 
achievable by optimising policies at the pixel level. 
Within individual countries, median provincial level 
savings were 72% (IQR 51–83) of those at the pixel level. 
Most cost savings obtained by tailoring control policies 
at the pixel level are achievable by optimising policies at 
the provincial scale. Exceptions are countries that have 
very large provinces (eg, DR Congo) or that have 
substantial transmission heterogeneity within provinces 
(eg, Zambia).
A Pixel level B Provincial level C National level
D Pixel level E Provincial level F National level
Required
combination
 ITN only
 ITN + IRS
 ITN + MDA
 ITN + IRS + MDA
0 5 10 15 20
Resources (US$), 
per person per year
Figure 4: Optimum combinations of interventions and minimum resources needed to achieve pre-elimination status across Africa
IRS=indoor residual spraying. ITN=insecticide-treated nets. MDA=mass drug administration. Upper maps show packages when policies are optimised at (A) pixel, 
(B) provincial, and (C) national levels. Lower maps show the resources needed to implement these packages at (D) pixel, (E) provincial, and (F) national levels.
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Table 2 shows that there is considerable heterogeneity 
between countries in the beneﬁ ts to be gained from more 
ﬁ ne-grained policies. Countries with areas of both very 
high and very low transmission (eg, Tanzania, Angola, 
Senegal, and Guinea) would save most from moving 
from a national-level to a provincial-level strategy. 
Cost of national 
policy (US$)
Saving with 
provincial policy 
(US$)*
Saving with provincial 
policy relative to 
national policy (%)
Further saving with 
pixel-level policy 
(US$)†
Saving with 
pixel-level policy 
relative to national 
policy (%)
Angola 25·7 (15·5–35·0) 9·5 (5·7–13·8) 37·5% (34·1–44·8) 5·7 (3·4–7·8) 59·8% (57·2–65·2)
Benin NP NP NP NP NP
Botswana 5·0 (3·3–7·0) 1·1 (0·6–2·0) 23·9% (14·6–30·9) 2·1 (1·2–3·1) 64·1% (52·0–70·7)
Burkina Faso NP NP NP NP NP
Burundi 10·8 (6·9–14·4) 6·6 (3·9–8·7) 59·1% (54·3–64·7) 0·6 (0·4–1·1) 65·8% (60·8–70·9)
Cameroon NP NP NP NP NP
Central African Republic 23·7 (14·6–32·7) 3·6 (2·3–6·8) 16·4% (12·0–23·8) 1·4 (0·8–1·9) 22·2% (18·6–29·8)
Congo (Brazzaville) 13·2 (8·4–18·2) 1·3 (0·5–2·1) 10·9% (4·4–13·2) 3·4 (2·1–4·9) 34·4% (31·0–39·5)
Côte D’Ivoire NP NP NP NP NP
Chad 14·2 (8·9–18·8) 5·9 (3·4–8·6) 42·4% (34·6–48·1) 1·6 (1·0–2·3) 53·6% (45·0–60·5)
Djibouti 0·8 (0·6–1·3) 0·4 (0·3–0·8) 53·5% (45·8–59·1) 0·0 (0·0–0·0) 53·5% (45·8–59·1)
DR Congo 20·9 (12·7–27·5) 2·4 (1·4–3·3) 11·6% (10·4–13·6) 5·2 (3·0–7·0) 36·1% (33·6–41·5)
Equatorial Guinea NP NP NP NP NP
Eritrea 5·0 (3·7–7·6) 3·0 (2·0–4·9) 61·4% (48·8–68·1) 0·2 (0·0–0·5) 65·1% (50·5–72·5)
Ethiopia 5·1 (3·8–7·7) 2·5 (1·5–4·1) 49·6% (36·5–57·8) 1·5 (1·1–2·2) 79·0% (66·4–85·4)
Gabon NP NP NP NP NP
Ghana NP NP NP NP NP
Guinea 19·4 (11·6–25·6) 7·6 (4·4–9·9) 38·8% (36·9–41·4) 2·7 (1·6–3·5) 52·6% (50·0–57·0)
Guinea-Bissau 16·0 (10·0–21·1) 7·1 (4·4–9·9) 45·0% (41·6–50·5) 3·4 (2·1–4·5) 66·4% (62·9–69·8)
Kenya NP NP NP NP NP
Liberia NP NP NP NP NP
Malawi NP NP NP NP NP
Mali NP NP NP NP NP
Mauritania 9·2 (5·9–12·4) 6·9 (4·1–9·2) 73·6% (69·3–76·5) 0·6 (0·4–0·9) 80·4% (75·7–82·3)
Mozambique NP NP NP NP NP
Namibia 9·0 (5·9–12·4) 3·3 (2·0–4·6) 36·1% (29·8–41·8) 0·9 (0·6–1·4) 46·2% (41·0–51·7)
Niger 19·4 (11·6–25·6) 2·4 (1·4–4·1) 13·1% (9·7–19·6) 4·8 (2·8–6·4) 38·1% (35·4–41·9)
Nigeria NP NP NP NP NP
Rwanda 5·0 (3·3–7·0) 3·1 (1·7–4·8) 61·3% (52·2–68·3) 0·6 (0·5–1·0) 75·0% (64·2–81·2)
Senegal 14·2 (8·9–18·8) 9·0 (5·5–12·3) 64·3% (60·6–66·4) 2·1 (1·2–2·8) 78·8% (74·8–81·2)
Sierra Leone 20·9 (12·7–27·5) 5·0 (2·9–6·6) 23·4% (22·1–24·7) 1·9 (1·1–2·9) 32·4% (30·7–36·7)
Somalia 1·0 (0·7–1·6) 0·0 (0·0–0·1) 5·1% (1·1–7·7) 0·1 (0·1–0·3) 17·7% (11·8–22·8)
South Africa 4·3 (2·6–5·8) 2·8 (1·5–4·2) 66·9% (53·5–73·1) 0·0 (0·0–0·1) 67·3% (55·4–73·1)
Sudan (including South Sudan)‡ 7·2 (5·0–10·1) 3·2 (2·0–4·5) 42·9% (39·5–48·0) 1·1 (0·8–1·8) 60·2% (55·1–62·6)
Swaziland 4·3 (2·6–5·8) 0·8 (0·4–1·3) 16·6% (10·1–22·3) 0·1 (0·0–0·3) 19·4% (14·4–26·2)
Tanzania 25·7 (15·5–35·0) 11·4 (6·8–15·7) 44·3% (42·3–48·0) 5·6 (3·2–7·4) 66·4% (62·7–69·9)
The Gambia 7·2 (5·0–10·1) 2·0 (1·2–3·5) 27·9% (23·3–36·3) 2·1 (1·2–3·1) 58·4% (46·4–62·5)
Togo NP NP NP NP NP
Uganda NP NP NP NP NP
Zambia 19·4 (11·6–25·6) 3·2 (1·9–4·5) 16·9% (15·6–20·1) 8·1 (4·7–10·5) 59·0% (54·8–62·1)
Zimbabwe 8·8 (5·5–11·7) 3·9 (2·3–5·4) 43·6% (39·1–49·7) 2·8 (1·8–4·3) 77·7% (71·5–81·3)
Median (IQR) 10·0 (5·0–19·4) 3·2 (2·4–6·4) 40·6% (18·5–52·5) 1·8 (0·6–3·25) 59·4% (40·1–66·4)
Total§ 14·3 (8·9–19·3) 4·5 (2·7–6·5) 32·1% (29·6–34·5) 3·1 (1·9–4·3) 53·4% (51·2–55·7)
Data are median (IQR) US$ in 2012, unless otherwise stated. Resources needed are assessed at the national level within mainland African countries with endemic malaria, with 
control policies stratiﬁ ed at diﬀ erent spatial scales. Variation in unit costs of delivering interventions between countries is not shown. NP=not possible to achieve pre-elimination 
levels of transmission in the country with any simulation. *Diﬀ erence in cost between policies optimised at the country and provincial level. †Diﬀ erence in cost between policies 
optimised at the provincial and pixel level. ‡Country boundaries are as of 2010. §Estimates weighted by population size in each country achieving pre-elimination.
Table 2: Estimated resources needed to achieve pre-elimination status, per person at risk per year 
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Countries with lower transmission but that still show 
high degrees of heterogeneity (eg, Mauritania, Zimbabwe, 
and Ethiopia) are also predicted to achieve very high 
proportional reductions with such a shift. By contrast, in 
countries where most of the population live in areas of 
high transmission (eg, Central African Republic, 
DR Congo, and Sierra Leone), the necessary resources to 
achieve elimination are likely to be high irrespective of 
the spatial scale at which interventions are deployed.
Discussion
In this analysis, we combined dynamic models of the 
eﬀ ect of malaria interventions with data for the resources 
needed to deploy them, to investigate how interventions 
can be optimised to achieve the various malaria control 
milestones necessary to achieve elimination. Our results 
serve to reiterate that universal coverage of long-lasting 
insecticide-treated nets should be a mainstay of any 
malaria control policy in Africa because it is the most 
cost-eﬃ  cient intervention to reduce both burden and 
transmission, irrespective of the ecology within a setting.
Our ﬁ ndings show that seasonal malaria chemo-
prevention is likely to be a more cost-eﬃ  cient means to 
reduce the clinical burden of malaria than is additional 
vector control in the form of indoor residual spraying, 
particularly in the highly seasonal settings in which it is 
currently recommended. Although not explicitly 
modelled, it seems highly plausible that other relatively 
low-cost, targeted strategies—eg, intermittent pre ventive 
treatment in infants and pregnant women—might also 
be part of an optimum package to reduce burden. 
However, because these interventions only reach a small 
proportion of the infectious reservoir,32 they are unlikely 
to reduce transmission substantially and, hence, increase 
the proportion of Africa in which elimination is 
achievable. By contrast, the addition of indoor residual 
spraying can allow additional areas to achieve 
elimination, particularly those in which vector behaviour 
is susceptible to indoor spraying—ie, where vectors are 
endophilic. We do not account for secular trends likely to 
aﬀ ect transmission over the next 20 years—eg, improve-
ments in housing, urbanisation, and climatic changes. 
However, our ﬁ nding that transmission cannot be driven 
below pre-elimination levels in more than half of Africa, 
even with 90% coverage, highlights that additional 
interventions will be necessary in many areas if 
elimination is ever likely to be feasible.
Our results show that mass drug administration is 
always strictly superior to mass screen and treatment if 
implemented at the same coverage level, for several 
reasons. First, in all but the lowest transmission settings, 
mass screen and treatment is a more expensive 
intervention, because of the need to pay for both the drug 
and the diagnostic. Second, some infections are missed 
with mass screen and treatment because of imperfect 
sensitivity of the diagnostic used for screening.33 Finally, 
mass drug administration provides additionally a period 
of prophylaxis for uninfected individuals who receive 
the drug.34
By tackling the asymptomatic and undetectable 
reservoir of infection, our ﬁ ndings show that mass drug 
administration could prove a valuable intervention to 
push more settings closer to elimination. However, such 
a strategy is likely to be highly resource intensive to 
maintain at a country level, particularly in higher 
transmission settings where multiple rounds of 
treatment per year are likely to be needed to achieve 
elimination goals. However, we noted that well calibrated, 
locally tailored policies could reduce substantially the 
areas and population in which such intensive measures 
are needed while achieving the same overall level of 
reduction in transmission. This tailoring has the 
additional beneﬁ t that the ﬁ nancial costs associated with 
such an intervention, and concerns around drug 
resistance with wide-scale mass drug administration, 
could be reduced greatly. The lower resources needed to 
achieve pre-elimination when interventions were 
targeted at 5 km² pixel resolution support the notion that 
such policies should operate as locally as is operationally 
feasible, particularly as elimination is approached and 
transmission becomes increasingly heterogeneous. 
At this stage, importation (which is not captured in 
our analysis) will become increasingly important. 
However, relative to a country-level policy to achieve pre-
elimination, our ﬁ ndings show that most cost savings 
achieved when optimising policies at such a high spatial 
resolution can be achieved at the subnational ﬁ rst 
administrative (provincial) level. This result suggests that 
large gains in allocative eﬃ  ciency are likely to be 
achievable through strengthening malaria surveillance 
in most settings, not just those with the resources to 
operate at very ﬁ ne spatial scales. These high potential 
returns on investment support the emphasis placed 
on ensuring malaria surveillance becomes a core 
intervention within malaria programmes, as outlined in 
the WHO Global Technical Strategy for malaria.12
In our analysis, we did not include variable ﬁ rst-line 
treatment rates within our optimum packages; instead, 
we included high treatment rates within all of our 
simulations. This rate was ﬁ xed partly because we judged 
adequate care for those with disease a prerequisite to any 
successful malaria control campaign but also because we 
did not have adequate data to calculate the resources 
needed to increase health-care capacity and attendance. 
However, since rigorous surveillance is likely to be a core 
focus of programme reorientation towards achieving and 
sustaining elimination,28 understanding these constraints 
will be fundamental to achieving further insight into 
where elimination is achievable.
Although we did sensitivity analyses, which take into 
account our uncertainty in the natural history of 
infection and key variables determining intervention 
eﬀ ectiveness, uncertainties remain in some of the other 
underlying model parameters. For example, the spatial 
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variation in vector abundance and their associated 
bionomics remain patchy but are important 
determinants of the eﬀ ect of vector control. Also 
important to note is that, because of scant empirical 
data, our estimates of the resources needed to deliver 
interventions do not capture economies of scale and 
scope, which can reduce costs when policies are widely 
deployed. Similarly, they do not encompass potential 
increases in costs associated with achieving very high 
coverage levels (eg, in targeting hard-to-reach 
populations) nor those associated with sustaining high 
coverage over time, especially in the context of 
transmission and the burden of disease falling to low 
levels. However, the framework we developed is 
suﬃ  ciently ﬂ exible for these factors to be incorporated 
with little additional computational expenditure if such 
eﬀ ects can be quantiﬁ ed adequately.
Our analysis suggests that elimination of malaria in 
many countries in Africa is unlikely to be possible even 
with 90% coverage of all currently recommended 
interventions (and with the option of three rounds of 
mass drug administration per year). This inability is 
especially sobering in view of the many other potential 
obstacles to malaria elimination—eg, development of 
resistance to drugs and insecticides35,36 and reported 
shifts in vector species distributions and behaviour.37,38 
Hence, our results show that sustained investment in the 
development of new, more eﬀ ective, malaria control 
interventions is vital if the goal of malaria elimination 
across Africa is to be realised. Nevertheless, the costs of 
deploying such additional strategies could be mitigated 
substantially by carefully assessed, subnational control 
strategies informed by the ecology of transmission at the 
local level.
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